Lipocine Inc. (NASDAQ: LPCN) announced that the last patient has completed the final study visit in its Phase 3 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE